Is it a lymphoma or a pseudotumour? This is the question that has to be faced every time a patient's proptosis is shown to be due to a localised proliferation of lymphocytes. In that a continuous spectrum of histological appearances may be seen from unmistakable chronic inflammation to undoubted malignancy, with many cases falling somewhere between, precise diagnosis can be extremely difficult. Hence the attraction of an additional approach to the differential diagnosis of lymphoproliferative disorders.
The traditional histopathological approach is geared to morphological assessment, but, fortunately, lesions involving lymphocytes also lend themselves to functional evaluation. A hypothesis that is fundamental to distinguishing between hyperplastic (reactive) and neoplastic lymphoid disorders is that a reactive process will cause a number of lymphocytes to respond, whereas a neoplastic lesion stems from a single abnormal cell. Thus both T and B lymphocytes can be expected to share in an inflammatory reaction, the latter cellsproducing avariety ofimmunoglobulins Correspondence to Professor A. Garner, Department of Pathology, Institute of Ophthalnology, 17-25 Cayton Street, London EC1V 9AT. which, while having the same antigenic specificity, will probably represent more than one class of immunoglobulin and almost certainly a mixture of kappa and lambda light chains. Conversely, neoplasia is considered to result from the mutation of a single cell so that, should the relevant cell be a B lymphocyte, all the immunoglobulin produced will be of one type with identical light chains.
To determine whether the lymphoproliferative lesions with an overwhelmingly monoclonal profile are truly neoplastic, in that if not already disseminated they do have a potential for metastasis, needs years of careful follow-up, and even then the diagnosis may remain unproved in patients who have received the treatment appropriate to such a presumption. Nevertheless, there are now several studies relating to the orbit and other sites which indicate that it may be practicable to differentiate between neoplastic (monoclonal) and hyperplastic (polyclonal) lymphocytic lesions by immunological methods.'s In the present paper we describe our interim findings in a long-term study of all patients presenting with suspected lymphoid pseudotumours to the Orbital Clinic of Moorfields Eye Hospital. 561 (Fig. 6) , which approximated to the K:X ratio of 2:1 pertaining in the circulating blood of the general population. The IgG levels were not significantly abnormal save in one patient (case 16) in whom there was a general reduction in serum immunoglobulin levels. Five of the 19 patients had serum IgA levels almost 2 standard deviations below the usual mean of 200 mg/dl (2 g/l) and 4 had serum IgM values that were considerably elevated above the normal mean of 130 mg/dl (1P3 g/l); in 2 the increase was far beyond 2 standard deviations. Autoantibodies were detected in the serum of 7 patients: in 3 the antibodies were directed against smooth muscle, in 3 they were antinuclear, and in 1 antireticulin.
The proportion of T cells in the peripheral blood is normally over 65%, but in 6 of the 19 cases it was below 60%. In no case where the capacity for lymphoblastic transformation was tested was there any evidence of functional deficiency in the T cells.
Discussion
In the absence of long-term follow-up it is impossible to substantiate the accuracy of diagnosis whether clinical, histological, or immunological criteria are used, particularly where the course of the disease has been modified by treatment. Irradiation is an effective treatment for both lymphoma and presumed reactive hyperplasia.3 It is probably significant, nevertheless, Fig. 3 Monoclonal lymphoproliferative lesions (lymphoma). The uniform mass ofpredominantly small lymphocytes is histologically indistinguishable from the polyclonal lesion depicted in Fig. 2 . In this case, however, there was a monoclonal immunohistochemical profile which together with the bland morphology suggests a lymphoma of low-grade malignancy. (Haematoxylin and eosin, x430) near monoclonal antibody production. The close correlation of polyclonality with clinical and histological evidence of chronic inflammation, while expected, is reassuring, but it is in the context of the lymphoid hyperplasia group that the chief interest lies. In a detailed morphological study of 22 adnexal lymphoid lesions, most of them involving the orbit, Jakobiec et al.3 found that 5 gave a polyclonal antibody profile and showed no evidence of the systemic involvement that might typify a lymphomatous process in a followup of up to 3 years. The follow-up period in our series is even shorter and does not warrant comparison, but it will be interesting to determine whether the 5 patients coming into this polyclonal lymphoproliferative category continue to be free of disease. For, while monoclonality is the characteristic of malignancy, there is growing evidence that nonmetastasising lymphocytic proliferations in alternative sites to the orbit can be polyclonal.67 Furthermore such hyperplastic polyclonal lesions may proceed on occasion to yield a monoclonal lymphoma as a result of subsequent mutation.6 The finding that the 3 patients with substantial fibrosis showed a polyclonal antibody picture is in keeping with the view that scar tissue formation is a postinflammatory event.
Jakobiec and his colleagues subdivided their monoclonal lesions on the basis of cytology and found that those characterised by well-differentiated small lymphocytes were free of systemic involvement after brief follow-up, whereas of those showing cytological irregularity slightly more than halfpresented evidence of disseminated disease. The morphology of the lymphoid infiltrates in the 5 patients in our own series with a monoclonal antibody reaction corresponds to the well-differentiated category and suggests a favourable outcome. Even so it is entirely reasonable to suppose that such 'benign' lymphoproliferative tumours may suffer further mutational events and develop into metastasising lymphomas.8 An increase in immature forms observed in repeat orbital biopsies in patients with lymphocytic proliferations has been reported.9 From the standpoint of management it seems appropriate to regard all monoclonal lesions as potential if not actual malignant lymphomas and to treat them accordingly. Indeed, unless the clinical and histological findings indicate an unequivocal inflammatory process, there is every reason to subject not only the monoclonal lesions but also polyclonal lymphoproliferative disorders to radiotherapy from the outset, the results in the 6 cases so treated in the present study being uniformly satisfactory (Table 3) .
IgM levels were elevated to above 200 mg/dl (2 g/l) in 4 patients, 2 of whom also had reduced proportions of circulating T cells. The mean IgM concentration in A. Garner, A. H. S. Rahi, andJ. E. Wright patients with low T cell counts was 268 mg/dl (2 7 g/l), whereas in patients with T cell counts of 60% or more the mean IgM level was 119 mg/dl (1 2 g/l). This could mean that the reduction in T cell numbers related principally to the suppressor subset, a deficiency of such cells having a permissive effect on IgM production. Now that specific antisera are available to enable the T cell subsets to be identified, steps to investigate this possibility are being taken and will be reported later.
Apart from one patient with low values for all the immunoglobulin fractions, IgG levels were essentially within normal limits.
However, in contrast to the IgM levels the IgA values were reduced in patients with low proportions of circulating T cells to a mean which was less than one-third of that for patients with normal T cell numbers. It is possible that the association is attributable to a deficiency of helper T cell function, and it may be relevant to note that Knowles and Jakobiec'°demonstrated just such a reduction in 2 of 6 patients with ocular lymphomas, although this would be to postulate a relative reduction of suppressor activity in respect of one class of antibody (IgM) and of the opposite in respect of IgA. An alternative is that both the T cell and the IgA deficiencies are separate manifestations of a more widely based inadequacy of immune function.
Autoantibodies were demonstrated in 7 patients, but the only tentative association was with IgA levels, 2 of the 5 such patients having circulating autoantibodies. A correlation between selective IgA deficiency and autoimmune disease has been reported previously,'1 and it appears that low levels of IgA carry an increased risk of developing inflammatory disease, autoimmunity, and neoplasia. Selective IgA deficiency is a fairly common abnormality in the population at large, and in a study of more than 4000 patients with a variety of ocular disorders (mainly inflammatory) Addison and Rahi'2 found that serum IgA levels below 60 mg/dl (0-6 g/l) occurred in 15%.
In the same study 17% of patients with malignant melanoma of the uvea had low IgA values. It is perhaps worth examining further the possibility that individuals with a reduced output of IgA and/or low numbers of circulating T cells have an enhanced risk of developing lymphoproliferative disease which may be inflammatory or neoplastic in nature.
Conclusions at this stage in our study must be tentative, but on the basis of the foregoing evidence, both our own and that of other workers, we suggest that 4 broad categories of orbital lymphoid proliferation can be identified:
(1) Unequivocal chronic inflammation. This may or may not be granulomatous but it will show a variety of types of leucocyte and present a polyclonal immunological profile.
(2) Polyclonal lymphoproliferative disease. An almost pure mass of mainly mature lymphocytes is associated with a mixture of antibody types. 
